Aphria Inc. Announces 158% Increase in Adult-Use Sales and Profitable Fourth Quarter

This Post Was Syndicated Under License Via QuoteMedia

Canada NewsWire

Reports Profitable Fourth Quarter
Record Net Revenue of $128.6 Million, Up 75% from Prior Quarter
Revenue for Adult-use Cannabis of $18.5 Million, Up 158% from Prior Quarter
Provides Fiscal Year 2020 Outlook

LEAMINGTON, ON, Aug. 1, 2019 /CNW/ – Aphria Inc. (“Aphria” or the “Company“) (TSX: APHA and NYSE: APHA) today reported its results for the fourth quarter and fiscal year ended May 31, 2019. All amounts are expressed in thousands of Canadian dollars, unless otherwise noted and except for per gram, kilogram, kilogram equivalents, and per share amounts.

Aphria Inc. (CNW Group/Aphria Inc.)

“It’s a new day at Aphria. Our team’s solid execution across key areas of our business resulted in strong adult-use revenue growth and a profitable fourth quarter,” stated Irwin D. Simon. “Over the last six months, our organization identified immediate priorities to help generate substantial progress near-term and long-term. We built upon existing business fundamentals and capabilities, streamlined processes, strengthened governance, and focused on building brand awareness. Together, we have nurtured an entrepreneurial culture of accountability through data-driven decision-making for value creation in the global medical and adult-use cannabis industry.  Today’s Aphria has a stronger foundation for long-term growth and success.”

Key Operating Highlights

  • Net revenue of $128.6 million in the fourth quarter, an increase of 75% from prior quarter and 969% from prior year.
  • Revenue for adult-use cannabis of $18.5 million in the fourth quarter, up 158% from prior quarter.
  • Net income of $15.8 million and adjusted EBITDA of $0.2 million in the fourth quarter.
  • Adjusted EBITDA from cannabis operations of $1.9 million in the fourth quarter.
  • Closed a 5.25% convertible senior notes offering for net proceeds of over US $335 million.
  • Ended quarter with a strong balance sheet and liquidity, including $571 million of cash, cash equivalents and liquid marketable securities, to fund planned Canadian and International growth.
  • Settlement of Green Growth Brands takeover bid resulting in $50 million cash received and an additional $39 million to be received in November.
  • Planted more than 200,000 plants in the new expanded area of Aphria One cultivation.
  • On-track for annual production capacity of 255,000 kilograms when all facilities are fully licensed.
  • Granted the maximum amount of lots within the German tender process, a total of five, and is the only licensed producer in Germany with the permission to grow all three strains of medical cannabis approved by the German Federal Institute for Drugs and Medical Devices.
  • Introduced a CBD-based nutraceutical product line for the German market.
  • Enhanced the executive team with appointment of several key positions.

 

Subsequent Events 

  • Signed on as a PAX Era brand partner for the PAX Era device and platform.
  • Aphria’s subsidiary Marigold Projects Jamaica Limited received a retail Herb House license from Jamaica’s Cannabis Licensing Authority to open its first store at the Peter Tosh Square, Unit #51, Pulse Center, 38a Trafalgar Road, overlooking the Peter Tosh Museum in New Kingston, Jamaica.

 

Key Financial Highlights

 

Three months ended

Three months ended

 

Twelve months ended

Twelve months ended

 

May 31, 2019

May 31, 2018

 

May 31, 2019

May 31, 2018

Net revenue

$128,568

$12,026

 

$237,110

$36,917

Gross profit

$36,007

$18,212

 

$75,421

$40,887

Adjusted cannabis gross profit 1

$15,165

$9,468

 

$40,596

$27,912

Adjusted cannabis gross margin 1

53.0%

78.7%

 

53.3%

75.6%

Adjusted distribution gross profit 1

$12,274

$0

 

$19,805

$0

Adjusted distribution gross margin 1

12.4%

0%

 

12.5%

0%

Net income (loss)

$15,760

($4,992)

 

($16,499)

$29,448

Adjusted EBITDA 1

$209

($1,162)

 

($27,720)

$4,341

           
           
 

Q4-2019

Q3-2019

     

Distribution revenue

$99,186

$57,599

     

Net cannabis revenue

$28,608

$15,438

     

Net revenue

$128,568

$73,582

     

Kilograms (or kilogram equivalents) sold 1

5,574.0

2,636.5

     

Cash cost to produce dried cannabis / gram 1

$1.35

$1.48

     

“All-in” cost of goods sold / gram 1

$2.35

$2.86

     

Adjusted EBITDA from cannabis operations 1

$1,851

($12,694)

     

Adjusted EBITDA from businesses under development 1

($5,514)

($3,990)

     

Adjusted EBITDA from distribution operations 1

$3,872

$2,249

     

Cash and cash equivalents & marketable securities

$570,996

$134,736

     

Working capital

$642,284

$131,278

     

Capital and intangible asset expenditures – wholly-owned subsidiaries 1

$26,828

$29,016

     

 

Net revenue for the three months ended May 31, 2019 was $128.6 million, compared to $73.6 million in the prior quarter and $12.0 million in the same period last year. Higher revenue in the quarter was driven by $99.2 million of distribution revenue from CC Pharma and other distribution companies and $33.5 million of revenue from cannabis produced. Net revenue includes over 3,228 kilogram equivalents sold for the adult-use market and 1,417 kilogram equivalents for medical cannabis sales.

The average retail selling price of medical cannabis (exclusive of wholesale), before excise tax, decreased to $7.66 per gram in the quarter, compared to $8.03 in the prior quarter, primarily related to a higher percentage of total medical sales coming from Aphria. The average selling price of adult-use cannabis, before excise tax, increased to $5.73 per gram in the quarter, compared to $5.14 per gram in the prior quarter.

Adjusted cannabis gross profit for the fourth quarter was $15.2 million, with an adjusted cannabis gross margin of 53.0%, compared to $7.6 million with an adjusted gross margin of 49.5% in the prior quarter. The increase in adjusted gross margin was primarily due to the increase in average selling price per gram in the quarter.

Adjusted distribution gross profit for the fourth quarter was $12.3 million, with an adjusted gross margin of 12.4%, compared to $7.8 million with an adjusted gross margin of 13.6% in the prior quarter.

Selling, general, and administrative costs in the quarter decreased to $62.4 million, from $106.6 million in the prior quarter and increased from $22.6 million in the prior year. The decrease from the prior quarter is mainly related to the decrease of $58 million in impairment expense and $11 million in share-based compensation, partially offset by $20 million in transaction costs primarily associated with the issuance of the senior convertible debenture.

Net income for the fourth quarter of 2019 was $15.8 million or $0.05 per share, compared to net loss of $108.2 million or $0.43 per share in the prior quarter, and net loss of $5.0 million or $0.04 per share for the same period last year. Excluding the non-cash impairment charges in the third quarter, adjusted net loss was $50.2 million, or $0.02 per share. The increase in net income was primarily due to the increase in sales and the net fair value adjustment for biological assets, and decrease in the impairment expense, offset by increase in SG&A related to G&A and transaction costs.

Adjusted EBITDA from cannabis operations for the fourth quarter was $1.9 million compared to a loss of $12.7 million in the prior quarter. The adjusted EBITDA loss from businesses under development for the fourth quarter was $5.5 million compared to a loss of $3.9 million in the prior quarter. Adjusted EBITDA from distribution operations for the fourth quarter was $3.9 million compared to $2.2 million in the prior quarter.  The increased adjusted EBITDA is primarily attributable to the increase in gross profit as explained above.

1 – In this press release, reference is made to adjusted cannabis gross profit, adjusted cannabis gross margin, adjusted distribution gross profit, adjusted distribution gross margin, adjusted net loss, adjusted EBITDA from cannabis operations, adjusted EBITDA from businesses under development, adjusted EBITDA from distribution operations, kilogram (or kilogram equivalents) sold, cash costs to produce dried cannabis per gram, “all-in” costs to produce dried cannabis per gram and investments in capital and intangible assets – wholly-owned subsidiaries, which are not measures of financial performance under International Financial Reporting Standards (IFRS).  These metrics and measures are not recognized measures under IFRS do not have meanings prescribed under IFRS and are as a result unlikely to be comparable to similar measures presented by other companies. These measures are provided as information complimentary to those IFRS measures by providing a further understanding of our operating results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of review of our financial information reported under IFRS. Definitions and reconciliations for all terms above can be found in the Company’s May 31, 2019 Management’s Discussion and Analysis, filed on SEDAR and EDGAR. 

Outlook

For fiscal year 2020, the Company expects:

  • Net revenue of approximately $650 million to $700 million, with distribution revenue representing slightly more than half of the total net revenue
  • Adjusted EBITDA of approximately $88 million to $95 million

 

Conference Call

Aphria executives will host a conference call to discuss these results today at 5:00 pm ET. To listen to the live call, dial (888) 231-8191 from Canada and the U.S. or (647) 427-7450 from International locations and use the passcode 5081017. A telephone replay will be available approximately two hours after the call concludes through August 15, 2019. To access the recording dial (855) 859-2056 and use the passcode 5081017.

There will also be a simultaneous, live webcast available on the Investors section of Aphria’s website at aphriainc.com. The webcast will be archived for 30 days.

We Have A Good Thing Growing

About Aphria

Aphria Inc. is a leading global cannabis company driven by an unrelenting commitment to our people, the planet, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been a leader in low-cost production of high-quality cannabis at scale, grown in natural conditions. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.

For more information, visit: aphriainc.com  

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws and are expressly qualified by this cautionary statement. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to revenue and Adjusted EBITDA guidance, internal expectations, estimated margins, expectations with respect to actual production volumes, expectations for future growing capacity and costs, the completion of any capital project or expansions, and expectations with respect to future production costs. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability of Aphria to meet its liquidity requirements to fund ongoing operations; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations.  

Readers are cautioned that the foregoing list is not exhaustive and should consider as other factors discussed under the heading “Risk Factors” in Aphria’s most recent Annual Information Form and MD&A for the financial year ended May 31, 2019 filed on SEDAR at www.sedar.com and in the United States on Edgar under Form 40-F at www.sec.gov.  Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.  Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Below schedule is an excerpt of Aphria Inc.’s financial statements prepared on a basis consistent with IFRS for the financial year ended May 31, 2019 filed on SEDAR at www.sedar.com and in the United States on Edgar under Form 40-F at www.sec.gov. This schedule does not contain all the information in Aphria Inc.’s annual report and Form 40-F that is important to you. You should read the financial statements and Form 40-F carefully to obtain a comprehensive understanding of Aphria Inc.’s financial statements under IFRS and related information.

Aphria Inc.
Consolidated Statements of Income and Comprehensive Income
(In thousands of Canadian dollars, except share and per share amounts)

         
       

For the year ended
May 31, 

     

Note

2019

2018

 

Revenue from cannabis produced

   

$  86,348

$  36,917

 

Distribution revenue

   

157,931

 

Other revenue

   

3,035

 

Excise taxes

   

(10,204)

           

Net revenue

   

237,110

36,917

           
 

Production costs

 

6

35,548

8,692

 

Cost of goods purchased

   

138,126

 

Other costs of sales

   

898

313

           

Gross profit before fair value adjustments

   

62,538

27,912

           
 

Fair value adjustment on sale of inventory

 

6

27,724

10,327

Capitalize off Cannabis
Sign up now to start receiving our investing insights for FREE!

 

 

Fair value adjustment on growth of biological assets

 

7

(40,607)

(23,302)

           

Gross profit

   

75,421

40,887

Operating expenses:

       
 

General and administrative

 

25

69,752

13,901

 

Share-based compensation

 

26

26,080

17,874

 

Selling, marketing and promotion

   

27,971

11,873

 

Amortization

   

14,084

3,985

 

Research and development

   

1,391

490

 

Impairment

 

11

58,039

 

Transaction costs

   

23,259

5,192

       

220,576

53,315

           

Operating loss 

   

(145,155)

(12,428)

           
 

Non-operating income

 

27

129,510

48,284

           

Income (loss) before income taxes

   

(15,645)

35,856

           

Income taxes

 

16

854

6,408

Net income (loss)

   

(16,499)

29,448

           

Other comprehensive loss

       
 

Other comprehensive loss

   

(119)

(801)

Net comprehensive income (loss)

   

$  (16,618)

$  28,647

           

Total comprehensive income (loss) is attributable to:

     
 

Shareholders of Aphria Inc.

   

(14,667)

28,867

 

Non-controlling interest

 

24

(1,951)

(220)

       

$  (16,618)

$  28,647

           

Weighted average number of common shares – basic

   

242,763,558

161,026,463

Weighted average number of common shares – diluted

   

242,763,558

165,914,000

           

Earnings (loss) per share – basic

 

29

$  (0.07)

$  0.18

Earnings (loss) per share – diluted

 

29

$  (0.07)

$  0.18

 

Aphria Inc.
Consolidated Statements of Financial Position
(In thousands of Canadian dollars)

           
     

Note

May 31,
2019

May 31,
2018

Assets

       

Current assets

       
 

Cash and cash equivalents

   

$  550,797

$  59,737

 

Marketable securities

 

4

20,199

45,062

 

Accounts receivable

   

25,488

3,386

 

Prepaids and other current assets

 

5

23,391

14,384

 

Inventory

 

6

91,529

22,150

 

Biological assets

 

7

18,725

7,331

 

Assets held for sale

   

40,620

 

Promissory notes receivable

 

15

39,200

 

Current portion of convertible notes receivable

 

12

11,500

1,942

       

780,829

194,612

 

Capital assets

 

9

503,898

303,151

 

Intangible assets

 

10

392,056

226,444

 

Convertible notes receivable

 

12

20,730

16,129

 

Interest in equity investees

 

13

9,311

4,966

 

Long-term investments

 

14

64,922

46,028

 

Goodwill

 

11

669,846

522,762

       

$  2,441,592

$  1,314,092

Liabilities

       

Current liabilities

       
 

Accounts payable and accrued liabilities

   

$  105,813

$  31,517

 

Income taxes payable

   

2,722

3,584

 

Deferred revenue

   

23,678

2,607

 

Current portion of promissory note payable

 

18

610

 

Current portion of long-term debt

 

19

6,332

2,140

 

Current portion of derivative liability

   

3,396

       

138,545

43,854

Long-term liabilities

       
 

Long-term debt

 

19

60,895

28,337

 

Convertible debentures

 

20

421,366

 

Derivative liability

   

9,055

 

Deferred tax liability

 

16

87,633

59,253

       

708,439

140,499

Shareholders’ equity

       
 

Share capital

 

21

1,655,273

1,113,981

 

Warrants

 

22

1,336

1,375

 

Share-based payment reserve

   

36,151

22,006

 

Accumulated other comprehensive loss

   

(119)

(801)

 

Non-controlling interest

 

24

28,409

9,580

 

Retained earnings 

   

12,103

27,452

       

1,733,153

1,173,593

       

2,441,592

$  1,314,092

 

 

Three months ended
May 31,

For the year ended
May 31,

2019

2018

2019

2018

Net income (loss)

$  15,760

$  (4,992)

$  (16,499)

$  29,448

Income taxes (recovery)

453

(1,731)

854

6,408

Non-operating (income) loss

(40,206)

2,351

(129,510)

(48,284)

Amortization

8,611

3,809

22,940

6,678

Share-based compensation

3,084

7,206

26,080

17,874

Fair value adjustment on sale of inventory

9,649

3,077

27,724

10,327

Fair value adjustment on growth of biological assets

(17,471)

(11,821)

(40,607)

(23,302)

Impairment

58,039

Transaction costs

20,329

939

23,259

5,192

Adjusted EBITDA from businesses under

       

development

5,514

2,834

16,240

2,834

Adjusted EBITDA from distribution operations

(3,872)

(6,036)

Adjusted EBITDA from cannabis

       

operations

$  1,851

$  1,672

$  (17,516)

$  7,175

 

 

Three months ended
May 31,

For the year ended
May 31,

2019

2018

2019

2018

Adjusted EBITDA from cannabis operations

$  1,851

$  1,672

$  (17,516)

$  7,175

Adjusted EBITDA from businesses under development

(5,514)

(2,834)

(16,240)

(2,834)

Adjusted EBITDA from distribution operations

3,872

6,036

Adjusted EBITDA

$  209

$  (1,162)

$  (27,720)

$  4,341

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aphria-inc-announces-158-increase-in-adult-use-sales-and-profitable-fourth-quarter-300895331.html

SOURCE Aphria Inc.

 

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2019/01/c1770.html

For media inquiries please contact: Tamara Macgregor, Vice President, Communications & Public Affairs, Aphria Inc., [email protected], 437-343-4000; For investor inquiries please contact: Katie M. Turner, ICR, Inc., [email protected], 646-277-1228Copyright CNW Group 2019

If You Liked This Article Click To Share